✦ LIBER ✦
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
✍ Scribed by Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y.; Amnon, A.; Bell-McGuinn, K. M.; Chen, L.-M.; Friedlander, M.
- Book ID
- 111868901
- Publisher
- American Society of Clinical Oncology
- Year
- 2012
- Tongue
- English
- Weight
- 165 KB
- Volume
- 30
- Category
- Article
- ISSN
- 0732-183X
No coin nor oath required. For personal study only.